通过荟萃分析评价火把花根片治疗慢性肾小球肾炎的疗效及安全性。

计算机检索PubMed、Embase、Web of science、Cochrane library、CNKI、Wan Fang、CBM、VIP等数据库，搜集火把花根片治疗慢性肾小球肾炎的随机对照试验，检索时限均从建库至2022年9月。按Cochrane协作网质量评价标准评价，提取有效数据，采用Revman 5.4软件进行荟萃分析，分析火把花根片对慢性肾小球肾炎的临床疗效。

最终共纳入8篇文献，共703例患者。荟萃分析结果显示：与对照组相比，火把花根片治疗组在提高临床有效率（RR=1.24，95%CI：1.04~1.48，P=0.02）、降低24h尿蛋白（MD=-1.51，95%CI：-2.47~-0.55，P=0.002）及血尿素氮（MD=-0.53，95%CI：-0.71~-0.34，P<0.00001）、改善血清白蛋白（MD=3.48，95%CI：2.72~4.25，P<0.00001）、减少尿红细胞（MD=-11.46，95%CI：-18.29~-4.64，P=0.001）等方面均有优势，但在降低血肌酐及不良反应方面与对照组差异均无统计学意义（均P>0.05）。

火把花根片对慢性肾小球肾炎有良好的疗效，但仍需更多大样本、多中心、高质量的随机对照试验数据支持。

To evaluate the efficacy and safety of Huobahuagen tablets for treating chronic glomerulonephritis by Meta-analysis.

The PubMed, Embase, Web of Science, Cochrane library, CNKI, Wan Fang, CBM, and VIP databases were searched by computer to collect randomized controlled trials of Huobahuagen tablets for treating chronic glomerulonephritis from the inception of the databases to September 2022. Effective data were extracted according to the quality evaluation standard of Cochrane Collaboration Network, and Revman 5.4 software was used for Meta-analysis to analyze the clinical efficacy of Huobahuagen tablets for chronic glomerulonephritis.

A total of 8 articles and 703 patients were included. The Meta-analysis results showed that compared with the control group, the Huobahuagen tablets treatment group had advantages of improving the clinical effective rate (relative risk [RR]=1.24, 95% confidence interval [CI]: 1.04-1.48, P=0.02), decreasing 24-hour urine protein (mean difference [MD]=-1.51, 95%CI: -2.47--0.55, P=0.002) and blood urea nitrogen (MD=-0.53, 95%CI: -0.71--0.34, P<0.00001), improving serum albumin (MD=3.48, 95%CI: 2.72-4.25, P<0.00001), and decreasing urine red blood cells (MD=-11.46, 95%CI: -18.29--4.64, P=0.001). However, there was no significant difference between the treatment group and the control group in reducing serum creatinine and adverse reactions (P>0.05 for both).

Huobahuagen tablets has a good effect in the treatment of chronic glomerulonephritis, but more evidence from large-sample, multi-center, high-quality randomized controlled trials is still required.